Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Boehringer Ingelheim670 enrolled

Overview

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Study Type

OBSERVATIONAL

Enrollment

670

Conditions

Hypertension

Interventions

MicardisDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. Patients who have recently been diagnosed with hypertension 2. Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion. Exclusion criteria: None (according to investigator)

Outcomes

Primary Outcomes

Efficacy (Change of Systolic Blood Pressure)

Change from baseline in 24h systolic blood pressure (BP) at week 8

Time frame: baseline to 8 weeks

Efficacy (Change of Diastolic Blood Pressure)

Change from baseline in 24h diastolic blood pressure (BP) at week 8

Time frame: baseline to 8 weeks

Secondary Outcomes

Overall Tolerability Scale

Safety and tolerability of Micardis® in the treatment of patients with hypertension over 8 weeks, using 10 point Likert scale with worst score=1, best score=10

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.